The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...
Hosted on MSN1d
Cancer treatment costs: 'I had to rob money from the money we’d set aside for my son’s wedding'Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, ...
Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug ...
The data cutoff date for the current analysis of the study was August 8, 2024. With 29.1 months of median follow-up, 12% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback